Societal CDMO Announces Signing of Multiple New CDMO Service Agreements
SAN DIEGO and GAINESVILLE, Ga., Oct. 20, 2022 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has signed CDMO service agreements with two new customers. These contracts are focused on a range of analytical method, technical transfer, formulation, manufacturing and packaging services designed to support ongoing development programs for novel therapeutic candidates.
Related news for (SCTL)
- Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
- Societal CDMO Reports Inducement Grants for New Staff
- Societal CDMO Reports Third Quarter 2023 Financial Results
- Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator
- Societal CDMO Reports Inducement Grants for New Staff